Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130225232910im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment.
PURPOSE: This research study is looking at methemoglobinemia in young patients with hematologic cancer or aplastic anemia treated with dapsone.
Condition | Intervention |
---|---|
Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Methemoglobinemia Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Nonmalignant Neoplasm |
Drug: chemotherapy Drug: dapsone Other: medical chart review Procedure: assessment of therapy complications |
Study Type: | Observational |
Official Title: | Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia |
- Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years [ Designated as safety issue: No ]
- Major risk factors for developing methemoglobinemia [ Designated as safety issue: No ]
Estimated Enrollment: | 200 |
Study Start Date: | January 2009 |
Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Define the incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years.
- Identify major risk factors for developing methemoglobinemia.
OUTLINE: Medical charts are reviewed. Of particular interest is demographic information, reasons for beginning dapsone prophylaxis, duration of dapsone prophylaxis, dapsone dosing, methemoglobin level, and treatment with methylene blue.
![](https://webarchive.library.unt.edu/web/20130225232910im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | up to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of hematologic malignancy or aplastic anemia
- Treated within the past 15 years with dapsone prophylaxis during treatment of primary disease
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
![](https://webarchive.library.unt.edu/web/20130225232910im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, Tennessee | |
Vanderbilt-Ingram Cancer Center - Cool Springs | |
Nashville, Tennessee, United States, 37064 | |
Vanderbilt-Ingram Cancer Center | |
Nashville, Tennessee, United States, 37232-6838 |
Principal Investigator: | Adam J. Esbenshade, MD | Vanderbilt-Ingram Cancer Center |
![](https://webarchive.library.unt.edu/web/20130225232910im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | Adam J. Esbenshade, Vanderbilt-Ingram Cancer Center |
ClinicalTrials.gov Identifier: | NCT00993694 History of Changes |
Other Study ID Numbers: | CDR0000652603, VU-VICC-PED-0916, IRB# 090009 |
Study First Received: | October 9, 2009 |
Last Updated: | November 4, 2010 |
Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
methemoglobinemia aplastic anemia accelerated phase chronic myelogenous leukemia acute undifferentiated leukemia atypical chronic myeloid leukemia, BCR-ABL negative blastic phase chronic myelogenous leukemia childhood acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood chronic myelogenous leukemia chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia juvenile myelomonocytic leukemia mast cell leukemia meningeal chronic myelogenous leukemia progressive hairy cell leukemia, initial treatment |
prolymphocytic leukemia recurrent childhood acute lymphoblastic leukemia recurrent childhood acute myeloid leukemia refractory chronic lymphocytic leukemia refractory hairy cell leukemia relapsing chronic myelogenous leukemia secondary acute myeloid leukemia stage 0 chronic lymphocytic leukemia stage I chronic lymphocytic leukemia stage II chronic lymphocytic leukemia stage III chronic lymphocytic leukemia stage IV chronic lymphocytic leukemia T-cell large granular lymphocyte leukemia AIDS-related diffuse large cell lymphoma AIDS-related diffuse mixed cell lymphoma |
Additional relevant MeSH terms:
Anemia Anemia, Aplastic Neoplasms Leukemia Lymphoma Lymphoproliferative Disorders Methemoglobinemia Multiple Myeloma Neoplasms, Plasma Cell Plasmacytoma Myelodysplastic Syndromes Preleukemia Myeloproliferative Disorders Lymphoma, Large-Cell, Immunoblastic Lymphoma, Non-Hodgkin |
Lymphoma, Large-Cell, Anaplastic Myelodysplastic-Myeloproliferative Diseases Hematologic Diseases Bone Marrow Diseases Neoplasms by Histologic Type Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hemorrhagic Disorders Precancerous Conditions |
ClinicalTrials.gov processed this record on February 24, 2013